Monitor PDUFA date June 25, 2027 for approval decision; watch for launch metrics and revenue ramp from the existing wild-type approval as a read-through for mutant cohort commercial potential.
Drug in focus
CELC drug pipeline →REVTORPYK
◆ Mixed Named in this press release- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially available in the US since September 30, 2026. A supplemental NDA (sNDA) for the PIK3CA mutant indication was submitted August 26, 2026; no PDUFA goal date has been publicly confirmed yet.
- Next catalyst
- None dated
What to watchWatch for the FDA's acceptance and PDUFA goal date for the sNDA covering the PIK3CA mutant indication, which would be the next major regulatory catalyst. Also monitor Q4 2026 earnings (expected early 2027) for the first meaningful product revenue figures and prescription trends. The stock's 126.5% implied upside to the mean analyst target reflects high expectations for commercial execution, so any launch stumbles could pressure the stock further.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $70.37entry
- T+1 · 7d ago −4.72%α −4.35% · $67.05
- T+5 · 18h ago −13.93%α −12.23% · $60.57
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Celcuity announced FDA acceptance of its sNDA for REVTORPYK (gedatolisib) in HR+/HER2- advanced breast cancer with PIK3CA mutations, with a PDUFA date of June 25, 2027. This expands the potential label to all HR+/HER2- advanced breast cancer patients regardless of PIK3CA status, building on the July 2026 approval for PIK3CA wild-type tumors.
Key Facts
- FDA accepted sNDA for REVTORPYK in HR+/HER2- advanced breast cancer with PIK3CA mutation
- PDUFA goal date set for June 25, 2027
- Submission based on PIK3CA mutant cohort of Phase 3 VIKTORIA-1 trial
- REVTORPYK already approved (July 14, 2026) for PIK3CA wild-type advanced breast cancer
- If approved, REVTORPYK would be available as second-line therapy regardless of PIK3CA status
- Gedatolisib previously received Breakthrough Therapy and Fast Track designations
- Approximately 40% of HR+/HER2- breast cancers have PIK3CA mutations
Financial Impact
Expands addressable patient population by ~40% (PIK3CA mutant) on top of existing wild-type approval; Celcuity is commercial-stage with $3.1B market cap, no product revenue yet (Q3 2026 net loss $73.3M)
Risk Factors
- FDA may issue a Complete Response Letter on safety/efficacy or CMC grounds
- Competition from other PI3K/AKT/mTOR inhibitors and CDK4/6 combinations
- Commercial execution risk given early launch stage and widening net losses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398409 |
Track record
26 reports on CELC
7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +26.84% at T+20 after the Jun 11, 2026 report. 9 of 12 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $62.58 Now $60.57 −3.21% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $64.37 Now $60.57 −5.90% settles Nov 23
- Nov 9, 20267d ago Press Release Bullish 5/10 Viewing Entry $70.37 to $60.57 Now $60.57 −13.93% ▼ −13.93% −12.23% vs SPY
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $66.79 to $64.37 Now $60.57 −9.31% ▼ −3.62% −6.22% vs SPY
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $69.72 to $67.05 Now $60.57 −13.12% ▼ −3.83% −3.24% vs SPY
- Oct 24, 202623d ago Press Release Bullish 6/10 Entry $65.80 to $69.13 Now $60.57 −7.95% ▲ +5.06% +6.32% vs SPY
- Oct 5, 20266w ago 3 Neutral 2/10 Entry $71.25 to $63.19 Now $60.57 −14.99% ▼ −11.31% −11.17% vs SPY
- Oct 2, 20266w ago 8-K Neutral 2/10 Entry $72.10 to $67.94 Now $60.57 −15.99% ▼ −5.77% −6.93% vs SPY
- Sep 30, 20266w ago 8-K Bullish 6/10 Entry $79.52 to $65.78 Now $60.57 −23.83% ▼ −17.28% −19.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers